BioWorld

Jan. 17, 2012

Record Year for Royalty Deals Builds Optimism for 2012

Not everyone is upset about the turmoil in the equity markets. Last year was a record year for the sale of royalty streams and other structured product deals, in large part because of the lack of other options for biotechs. Read More

Too Many Trials Still Published At a Glacial Pace, or Not at All

Supposedly, academia's battle cry is "publish or perish." So why are so many clinical trials going unpublished? Read More

Week in Review

Word on the Street

Week in Washington

Biotech Restructurings, Expansions, Scale-Backs, Bankruptcies: Jan. 1 - Dec. 31, 2011

Biotech Lawsuits: Jan. 1 - Dec. 31, 2011

Money Raised By Biotech In 2012 Vs. 2011

Money Raised By Biotech: Jan. 1 - 13, 2012

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 15, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...

Microscopic image of chronic myeloid leukemia

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

BioWorld

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...